The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations
The safety profile of new antidiabetic xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7), administrated to diabetic rats, have been evaluated in terms of biochemical markers of liver and kidney function as well as of hematological mar...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmaceutical sciences 2019-01, Vol.127, p.71-78 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 78 |
|---|---|
| container_issue | |
| container_start_page | 71 |
| container_title | European journal of pharmaceutical sciences |
| container_volume | 127 |
| creator | Lupascu, Florentina Geanina Giusca, Simona-Eliza Caruntu, Irina-Draga Anton, Alina Lupușoru, Cătălina Elena Profire, Lenuta |
| description | The safety profile of new antidiabetic xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7), administrated to diabetic rats, have been evaluated in terms of biochemical markers of liver and kidney function as well as of hematological markers. The effect on lipid profile and clinic parameters (body weight, food and water intake) has been also evaluated. The treatment of diabetic rats with xanthine derivatives (6, 7) and chitosan based formulations (CS-6, CS-7) was associated with lower liver enzymes (AST, ALT, LDH) and bilirubin (direct, total) values compared to the non-treated diabetic rats, that means the tested derivatives/formulations have improved the liver function injured in diabetes mellitus conditions. Also the kidney biochemical markers (creatinine, uric acid, urea) were significantly decreased in diabetic rats treated with 6, 7 and chitosan microparticles (CS-6, CS-7). The values of biochemical markers of liver and kidney functions were even better than the values recorded for pioglitazone, used as standard antidiabetic drug. The improving effect on kidney function was proved by the histopathological study. Moreover, the xanthine derivatives and their chitosan based formulation were associated with improved hematological markers compared to the non-treated diabetic rats which mean the improving of the hemorheological state. These results support the safety profile of new xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7) and their potential applications for the treatment of diabetes mellitus syndrome.
[Display omitted] |
| doi_str_mv | 10.1016/j.ejps.2018.10.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2123720860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098718304627</els_id><sourcerecordid>2123720860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-a3ff2bc3f9ac7bda2c1c194ea2e33e43cce60b22ae2b28b35103cd1a1807ad313</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotn78AQ-So5etk8TuB3iR4hcUvOg5zCYTmrLdrUla9d-bUvXoaZiXZ16Yh7ELARMBorxeTmi5jhMJos7BBMT0gI1FXTUFVBIO2RgaWRfQ1NWIncS4BICyruCYjRQolWMYM3xdEI_oKH3xdRic74gPjvf0wbFP3npsKXnDP_O28D1xS8FvMfktxUxYnhbkAzcLn4aIPW8xkuVuCKtNl6mhj2fsyGEX6fxnnrK3h_vX2VMxf3l8nt3NC6OmZSpQOSdbo1yDpmotSiOMaG4IJSlFN8oYKqGVEkm2sm7VVIAyVqCooUKrhDplV_ve_Mb7hmLSKx8NdR32NGyilkKqrKUuIaNyj5owxBjI6XXwKwxfWoDeqdVLvVOrd2p3WVabjy5_-jftiuzfya_LDNzuAcpfbj0FHY2n3pD1gUzSdvD_9X8D6K-MsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2123720860</pqid></control><display><type>article</type><title>The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lupascu, Florentina Geanina ; Giusca, Simona-Eliza ; Caruntu, Irina-Draga ; Anton, Alina ; Lupușoru, Cătălina Elena ; Profire, Lenuta</creator><creatorcontrib>Lupascu, Florentina Geanina ; Giusca, Simona-Eliza ; Caruntu, Irina-Draga ; Anton, Alina ; Lupușoru, Cătălina Elena ; Profire, Lenuta</creatorcontrib><description>The safety profile of new antidiabetic xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7), administrated to diabetic rats, have been evaluated in terms of biochemical markers of liver and kidney function as well as of hematological markers. The effect on lipid profile and clinic parameters (body weight, food and water intake) has been also evaluated. The treatment of diabetic rats with xanthine derivatives (6, 7) and chitosan based formulations (CS-6, CS-7) was associated with lower liver enzymes (AST, ALT, LDH) and bilirubin (direct, total) values compared to the non-treated diabetic rats, that means the tested derivatives/formulations have improved the liver function injured in diabetes mellitus conditions. Also the kidney biochemical markers (creatinine, uric acid, urea) were significantly decreased in diabetic rats treated with 6, 7 and chitosan microparticles (CS-6, CS-7). The values of biochemical markers of liver and kidney functions were even better than the values recorded for pioglitazone, used as standard antidiabetic drug. The improving effect on kidney function was proved by the histopathological study. Moreover, the xanthine derivatives and their chitosan based formulation were associated with improved hematological markers compared to the non-treated diabetic rats which mean the improving of the hemorheological state. These results support the safety profile of new xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7) and their potential applications for the treatment of diabetes mellitus syndrome.
[Display omitted]</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/j.ejps.2018.10.015</identifier><identifier>PMID: 30339870</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Biochemical markers ; Chitosan ; Chitosan - administration & dosage ; Diabetes mellitus ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - metabolism ; Diabetes Mellitus, Experimental - pathology ; Hematologic Tests ; Hematological markers ; Hypoglycemic Agents - administration & dosage ; Kidney - drug effects ; Kidney - pathology ; Lipid Metabolism - drug effects ; Liver - drug effects ; Liver - metabolism ; Rats ; Thiazolidines - administration & dosage ; Xanthine derivatives ; Xanthines - administration & dosage</subject><ispartof>European journal of pharmaceutical sciences, 2019-01, Vol.127, p.71-78</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-a3ff2bc3f9ac7bda2c1c194ea2e33e43cce60b22ae2b28b35103cd1a1807ad313</citedby><cites>FETCH-LOGICAL-c356t-a3ff2bc3f9ac7bda2c1c194ea2e33e43cce60b22ae2b28b35103cd1a1807ad313</cites><orcidid>0000-0002-7953-3023</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejps.2018.10.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30339870$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lupascu, Florentina Geanina</creatorcontrib><creatorcontrib>Giusca, Simona-Eliza</creatorcontrib><creatorcontrib>Caruntu, Irina-Draga</creatorcontrib><creatorcontrib>Anton, Alina</creatorcontrib><creatorcontrib>Lupușoru, Cătălina Elena</creatorcontrib><creatorcontrib>Profire, Lenuta</creatorcontrib><title>The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>The safety profile of new antidiabetic xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7), administrated to diabetic rats, have been evaluated in terms of biochemical markers of liver and kidney function as well as of hematological markers. The effect on lipid profile and clinic parameters (body weight, food and water intake) has been also evaluated. The treatment of diabetic rats with xanthine derivatives (6, 7) and chitosan based formulations (CS-6, CS-7) was associated with lower liver enzymes (AST, ALT, LDH) and bilirubin (direct, total) values compared to the non-treated diabetic rats, that means the tested derivatives/formulations have improved the liver function injured in diabetes mellitus conditions. Also the kidney biochemical markers (creatinine, uric acid, urea) were significantly decreased in diabetic rats treated with 6, 7 and chitosan microparticles (CS-6, CS-7). The values of biochemical markers of liver and kidney functions were even better than the values recorded for pioglitazone, used as standard antidiabetic drug. The improving effect on kidney function was proved by the histopathological study. Moreover, the xanthine derivatives and their chitosan based formulation were associated with improved hematological markers compared to the non-treated diabetic rats which mean the improving of the hemorheological state. These results support the safety profile of new xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7) and their potential applications for the treatment of diabetes mellitus syndrome.
[Display omitted]</description><subject>Animals</subject><subject>Biochemical markers</subject><subject>Chitosan</subject><subject>Chitosan - administration & dosage</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetes Mellitus, Experimental - pathology</subject><subject>Hematologic Tests</subject><subject>Hematological markers</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Lipid Metabolism - drug effects</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Rats</subject><subject>Thiazolidines - administration & dosage</subject><subject>Xanthine derivatives</subject><subject>Xanthines - administration & dosage</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotn78AQ-So5etk8TuB3iR4hcUvOg5zCYTmrLdrUla9d-bUvXoaZiXZ16Yh7ELARMBorxeTmi5jhMJos7BBMT0gI1FXTUFVBIO2RgaWRfQ1NWIncS4BICyruCYjRQolWMYM3xdEI_oKH3xdRic74gPjvf0wbFP3npsKXnDP_O28D1xS8FvMfktxUxYnhbkAzcLn4aIPW8xkuVuCKtNl6mhj2fsyGEX6fxnnrK3h_vX2VMxf3l8nt3NC6OmZSpQOSdbo1yDpmotSiOMaG4IJSlFN8oYKqGVEkm2sm7VVIAyVqCooUKrhDplV_ve_Mb7hmLSKx8NdR32NGyilkKqrKUuIaNyj5owxBjI6XXwKwxfWoDeqdVLvVOrd2p3WVabjy5_-jftiuzfya_LDNzuAcpfbj0FHY2n3pD1gUzSdvD_9X8D6K-MsQ</recordid><startdate>20190115</startdate><enddate>20190115</enddate><creator>Lupascu, Florentina Geanina</creator><creator>Giusca, Simona-Eliza</creator><creator>Caruntu, Irina-Draga</creator><creator>Anton, Alina</creator><creator>Lupușoru, Cătălina Elena</creator><creator>Profire, Lenuta</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7953-3023</orcidid></search><sort><creationdate>20190115</creationdate><title>The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations</title><author>Lupascu, Florentina Geanina ; Giusca, Simona-Eliza ; Caruntu, Irina-Draga ; Anton, Alina ; Lupușoru, Cătălina Elena ; Profire, Lenuta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-a3ff2bc3f9ac7bda2c1c194ea2e33e43cce60b22ae2b28b35103cd1a1807ad313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Biochemical markers</topic><topic>Chitosan</topic><topic>Chitosan - administration & dosage</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetes Mellitus, Experimental - pathology</topic><topic>Hematologic Tests</topic><topic>Hematological markers</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Lipid Metabolism - drug effects</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Rats</topic><topic>Thiazolidines - administration & dosage</topic><topic>Xanthine derivatives</topic><topic>Xanthines - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lupascu, Florentina Geanina</creatorcontrib><creatorcontrib>Giusca, Simona-Eliza</creatorcontrib><creatorcontrib>Caruntu, Irina-Draga</creatorcontrib><creatorcontrib>Anton, Alina</creatorcontrib><creatorcontrib>Lupușoru, Cătălina Elena</creatorcontrib><creatorcontrib>Profire, Lenuta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lupascu, Florentina Geanina</au><au>Giusca, Simona-Eliza</au><au>Caruntu, Irina-Draga</au><au>Anton, Alina</au><au>Lupușoru, Cătălina Elena</au><au>Profire, Lenuta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2019-01-15</date><risdate>2019</risdate><volume>127</volume><spage>71</spage><epage>78</epage><pages>71-78</pages><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>The safety profile of new antidiabetic xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7), administrated to diabetic rats, have been evaluated in terms of biochemical markers of liver and kidney function as well as of hematological markers. The effect on lipid profile and clinic parameters (body weight, food and water intake) has been also evaluated. The treatment of diabetic rats with xanthine derivatives (6, 7) and chitosan based formulations (CS-6, CS-7) was associated with lower liver enzymes (AST, ALT, LDH) and bilirubin (direct, total) values compared to the non-treated diabetic rats, that means the tested derivatives/formulations have improved the liver function injured in diabetes mellitus conditions. Also the kidney biochemical markers (creatinine, uric acid, urea) were significantly decreased in diabetic rats treated with 6, 7 and chitosan microparticles (CS-6, CS-7). The values of biochemical markers of liver and kidney functions were even better than the values recorded for pioglitazone, used as standard antidiabetic drug. The improving effect on kidney function was proved by the histopathological study. Moreover, the xanthine derivatives and their chitosan based formulation were associated with improved hematological markers compared to the non-treated diabetic rats which mean the improving of the hemorheological state. These results support the safety profile of new xanthine derivatives with thiazolidine‑4‑one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7) and their potential applications for the treatment of diabetes mellitus syndrome.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30339870</pmid><doi>10.1016/j.ejps.2018.10.015</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7953-3023</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0928-0987 |
| ispartof | European journal of pharmaceutical sciences, 2019-01, Vol.127, p.71-78 |
| issn | 0928-0987 1879-0720 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2123720860 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Animals Biochemical markers Chitosan Chitosan - administration & dosage Diabetes mellitus Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - metabolism Diabetes Mellitus, Experimental - pathology Hematologic Tests Hematological markers Hypoglycemic Agents - administration & dosage Kidney - drug effects Kidney - pathology Lipid Metabolism - drug effects Liver - drug effects Liver - metabolism Rats Thiazolidines - administration & dosage Xanthine derivatives Xanthines - administration & dosage |
| title | The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T08%3A14%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20safety%20profile%20of%20new%20antidiabetic%20xanthine%20derivatives%20and%20their%20chitosan%20based%20formulations&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Lupascu,%20Florentina%20Geanina&rft.date=2019-01-15&rft.volume=127&rft.spage=71&rft.epage=78&rft.pages=71-78&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/j.ejps.2018.10.015&rft_dat=%3Cproquest_cross%3E2123720860%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2123720860&rft_id=info:pmid/30339870&rft_els_id=S0928098718304627&rfr_iscdi=true |